



(11) **EP 3 527 584 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
C07K 14/705^(2006.01)

(48) Corrigendum issued on:
16.12.2020 Bulletin 2020/51

(45) Date of publication and mention
of the grant of the patent:
14.10.2020 Bulletin 2020/42

(21) Application number: **19152955.1**

(22) Date of filing: **22.05.2013**

(54) **MEDICAL USE OF CELLS COMPRISING ANTI-NY-ESO-1 T CELL RECEPTORS**

MEDIZINISCHE VERWENDUNG VON ZELLEN DIE ANTI-NY-ESO-1 T-ZELLREZEPTOREN
BEINHALTEN

L'UTILISATION DES CELLULES QUI CONTIENENT DES RÉCEPTEURS DES LYMPHOCYTES T
ANTI-NY-ESO-1 DANS LA MEDICINE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **22.05.2012 US 201261650020 P**

(43) Date of publication of application:
21.08.2019 Bulletin 2019/34

(60) Divisional application:
20201340.5

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
13726389.3 / 2 852 613

(73) Proprietor: **The United States of America, as
represented by
the Secretary, Department of Health and
Human Services
Bethesda, MD 20892-7660 (US)**

(72) Inventors:
• **PARKHURST, Maria R.
Ellicott City, MD 21043 (US)**
• **MORGAN, Richard Arthur
Center Harbor, NH 03226 (US)**
• **ROSENBERG, Steven A.
Potomac, MD 20854 (US)**
• **ROSATI, Shannon Faith
Richmond, VA 23224 (US)**

(74) Representative: **Grünecker Patent- und
Rechtsanwälte
PartG mbB
Leopoldstraße 4
80802 München (DE)**

(56) References cited:
WO-A2-2009/042570

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 527 584 B8

- **ROBBINS PAUL F ET AL: "Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 MAR 2011, vol. 29, no. 7, 1 March 2011 (2011-03-01), pages 917-924, XP002705979, ISSN: 1527-7755**
- **JENNIFER A WARGO ET AL: "Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 58, no. 3, 2 August 2008 (2008-08-02) , pages 383-394, XP019706282, ISSN: 1432-0851**
- **LEE L ET AL: "NY-ESO-1 MAY BE A POTENTIAL TARGET FOR LUNG CANCER IMMUNOTHERAPY", CANCER JOURNAL FROM SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN, INC., NEW YORK, NY, US, vol. 5, no. 1, 1 January 1999 (1999-01-01) , pages 20-25, XP001015618, ISSN: 1081-4442**